Synthetic Biologics Inc (NYSEMKT:SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced that it has been granted new patents in Europe and has received a notice of allowance in Australia that provide composition of matter coverage for various aspects of its C. difficile (C. diff) program. The Company’s extensive C. diff patent estate now includes over 25 U.S. and international patents. Synthetic Biologics Inc (NYSEMKT:SYN), weekly performance is -11.81%. On last trading day company shares ended up $1.27. Analysts mean target price for the company is $3.95. Synthetic Biologics Inc (NYSEMKT:SYN), distance from 50-day simple moving average (SMA50) is -50.92%.
CEL-SCI Corporation (NYSEMKT:CVM), Product Pipeline Review – 2014 is a new market research publication announced by Reportstack. CEL-SCI Corporation (NYSEMKT:CVM), shares fell 9.24% in last trading session and ended the day on $1.08. CVM, return on assets is -71.40%. CEL-SCI Corporation (NYSEMKT:CVM), quarterly performance is 16.13%.
On May 07, 2014, Nektar Therapeutics (NASDAQ:NKTR), reported its financial results for the first quarter ended March 31, 2014. Nektar Therapeutics (NASDAQ:NKTR), shares moved down 3.03% in last trading session and was closed at $10.88, while trading in range of $ 10.61 – 11.86. Nektar Therapeutics (NASDAQ:NKTR), year to date (YTD) performance is -4.14%.
Northwest Biotherapeutics, Inc (NASDAQ:NWBO), a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, announced that ASCO (the American Society for Clinical Oncology) has announced in its Annual Meeting program that the Company will present its DCVax-Direct clinical trial and technology in a general poster session at this year’s ASCO meeting, taking place in Chicago May 30 through June 3. The abstract is number TPS3133, and the poster is number 189(a). Northwest Biotherapeutics, Inc (NASDAQ:NWBO), ended the last trading day at $4.94. Company weekly volatility is calculated as 7.18% and price to cash ratio as 14.96. Northwest Biotherapeutics, Inc (NASDAQ:NWBO), showed a negative weekly performance of 16.27%.